华兰股份拟斥4.5亿元增资灵擎数智 完善AI医药领域战略布局

Core Viewpoint - The company has approved a capital increase of 450 million yuan for its wholly-owned subsidiary, Hainan Lingqing Smart Pharmaceutical Technology Co., Ltd., which focuses on AI-driven drug development solutions and services [1] Group 1: Company Strategy - The capital increase aims to enhance the company's strategic layout in the AI pharmaceutical sector [1] - The investment will strengthen the company's capability for continuous investment in cutting-edge technologies and industry collaboration [1] - This move is expected to promote the steady development and commercialization of the company's AI pharmaceutical business [1]